Evidence for the heterotetrameric structure of the adenosine A2A-dopamine D2 receptor complex

Heteromers of G-protein-coupled receptors (GPCRs) have emerged as potential novel targets for drug development. Accumulating evidence indicates that GPCRs can form homodimers and heteromers, with homodimers being the predominant species and oligomeric receptors being formed as multiples of dimers. Recently, heterotetrameric structures have been proposed for dopamine D-1 receptor (D1R)-dopamine D-3 receptor (D3R) and adenosine A(2A) receptor (A(2A)R)-dopamine D-2 receptor (D2R) heteromers. The structural model proposed for these complexes is a heteromer constituted by two receptor homodimers. The existence of GPCR homodimers and heteromers provides a structural basis for inter-protomer allosteric mechanisms that might account for a multiplicity of unique pharmacological properties. In this review, we focus on the A(2A)R-D2R heterotetramer as an example of an oligomeric structure that is key in the modulation of striatal neuronal function. We also review the interfaces involved in this and other recently reported heteromers of GPCRs. Furthermore, we discuss several published studies showing the ex vivo expression of A(2A)R-D2R heteromers. The ability of A(2A)R agonists to decrease the affinity of D2R agonists has been reported and, on the basis of this interaction, A(2A)R antagonists have been proposed as potential drugs for the treatment of Parkinson's disease. The heterotetrameric structure of the A(2A)R-D2R complex offers a novel model that can provide new clues about how to adjust the drug dosage to the expected levels of endogenous adenosine.